Alluvi, formerly BI 4744, presents a significant breakthrough in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates impressive effectiveness in patient trials, possibly surpassing https://bookmarkcitizen.com/story22121788/alluvi-a-in-depth-dive-into-retatrutide-s-prospects